TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01392157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: copper-releasing intrauterine device
Description: 100 women received a 380 mm2 of copper releasing intrauterine device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENG-releasing implant
Description: 60 mcg/day releasing etonogestrel implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENG-releasing implant
Description: 60 mcg/day releasing etonogestrel implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENG-releasing implant
Description: 60 mcg/day releasing etonogestrel implant

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-releasing intrauterine system
Description: a LNG-IUS releasing 20 mcd/day of LNG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-releasing intrauterine system
Description: a LNG-IUS releasing 20 mcd/day of LNG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-releasing intrauterine system
Description: a LNG-IUS releasing 20 mcd/day of LNG
Study: NCT03614546

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity-modulated Radiation Therapy (IMRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity-modulated Radiation Therapy (IMRT)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity-modulated Radiation Therapy (IMRT)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hepatectomy
Description: Hepatectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization (TACE)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization (TACE)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization (TACE)
Study: NCT01392157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: 100 women will receive an LNG-IUS
Study: NCT03614546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization (TACE)
Study: NCT03686891

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin prick tests with four native legumes
Description: Skin prick tests with four native legumes
Study: NCT02947516

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous liver biopsy
Description: Participants will undergo percutaneous liver biopsy per standard protocol.
Study: NCT00757770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two oral doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two oral doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two oral doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
Study: NCT02537704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Program
Study: NCT01228916

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation and Secondhand Smoke Reduction
Description: Awareness raising and resources for cessation and secondhand smoke reduction
Study: NCT01429792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: standard treatment, subcutaneously weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: standard treatment, orally daily
Study: NCT04433429

Intervention type: DIETARY_SUPPLEMENT
Intervention: Liposcudil Plus
Study: NCT02599935

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypercaloric beverages
Description: Nutritional supplement: Hypercaloric beverages

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: No other than standard treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational structured counseling
Description: Nutritional counseling leaded to patient and caregivers
Study: NCT04299984

Intervention type: PROCEDURE
Intervention: Open Conversion after EVAR
Description: See Open Conversions group description.

Intervention type: PROCEDURE
Intervention: SemiConversion after EVAR
Description: See SemiConversions group description.
Study: NCT01948648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of fish oil and colesevelam
Description: combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
Study: NCT04820439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)
Description: A single intravenous infusion of HS627 420mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta ®
Description: A single intravenous infusion of Perjeta ®420mg
Study: NCT01043263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3324 (axomadol)
Description: twice daily dosing

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily dosing
Study: NCT00476255

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard Care (ESC)
Description: Reading material

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Description: Motivational interview with trained therapist
Study: NCT00790790

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: LY545694 placebo BID po for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 49 mg
Description: LY545694 49 mg BID po for 5 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY545694 105 mg
Description: LY545694 105 mg BID po for 5 weeks.
Study: NCT04001517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neflamapimod
Description: Double-Blind, Placebo-Controlled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neflamapimod
Description: Double-Blind, Placebo-Controlled
Study: NCT01787773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veniti Inferior Vena Cava Filter
Study: NCT03312309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: personal embryo transfer
Description: According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .~The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .~pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles.
Study: NCT01147380

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver NK cell inoculation
Description: Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Liver NK cell inoculation
Description: Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
Study: NCT03783754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan 20 mg + amlodipine 2.5mg + indapamide 1.25mg
Description: low-dose combination therapy
Study: NCT04191421

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Siltuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Given IV
Study: NCT02529293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BioChaperone Lispro U-100
Description: Injection of BioChaperone Lispro U-100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BioChaperone Lispro U-200
Description: Injection of BioChaperone Lispro U-200
Study: NCT02560831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise and Pompage
Description: Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational lectures
Description: Educational lectures in four meetings for 12 weeks (Control Group)
Study: NCT03783754

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: matched placebo
Study: NCT03768869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Risk: Oupatient Management
Description: Intravenous Levaquin initially, then oral dosing. Patient discharged to go home to finish medication cycle after initial 120 minutes observation. Patients will be evaluated daily in the clinic, and his or her temperature must be taken and recorded four times per day. Blood cultures will be drawn at clinic visits.
Study: NCT01392157

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: 100 women will receive an LNG-IUS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: 100 women will receive an LNG-IUS
Study: NCT03241563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Deoxycholate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Deoxycholate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone 40mg/ml
Study: NCT04748887

Intervention type: OTHER
Intervention: oxidative stess markers
Description: markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .

Intervention type: OTHER
Intervention: oxidative stess markers
Description: markers of oxidative stress , Superoxide Dismutase (SOD) and Malondialdehyde (MDA) by ( ELISA Kit SinoGeneClon Biotech Co.,Ltd Catalog No : SG- 10188) .
Study: NCT04106505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback training via app on smartphone
Description: Biofeedback training as described in biofeedback arm.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham-biofeedback training via app on smartphone
Description: Sham-biofeedback training as described in sham-biofeedback arm.
Study: NCT04028830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC
Description: Visit to GPs to promote good antibiotic prescription with the help internet tool for decision: ANTIBIOCLIC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
Description: Visit to GPs to promote good antibiotic prescription without presentation of the internet tool for decision support
Study: NCT00105898

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Web-based care management
Description: Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
Study: NCT03768869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low Risk: Inpatient Management
Description: Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
Study: NCT05097274

Intervention type: OTHER
Intervention: MRI pelvis or CT imaging under clinical management for Pr Ca
Description: Individuals to undergo a clinical MRI or CT scan of Pelvis and the study reviews the images.

Intervention type: OTHER
Intervention: Whole body bone scan imaging
Description: bone scan of the whole body (under clinical diagnosis).

Intervention type: OTHER
Intervention: PET-CT imaging
Description: Pt will undergo a PET-CT for their clinical treatment and we will review the images of this scan.
Study: NCT00105898

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telephone and face-to-face care management
Description: Participants interact with a care manager via face-to-face and telephone contact

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Internet access alone
Description: Participants are given internet access and encouraged to seek diabetes information to help in their self management
Study: NCT02733757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 1 µg/kg plus 2% lidocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 1 µg/kg plus 2% lidocaine
Study: NCT02135484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpharadin
Description: 50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
Study: NCT00895804

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: capsule, 1.6 mg/kg body weight, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: MDMA
Description: capsule, 1.6 mg/kg body weight, single dose

Intervention type: DRUG
Group type: OTHER
Intervention: Pindolol
Description: capsule of 20mg pindolol, single dose 1h before MDMA

Intervention type: DRUG
Group type: OTHER
Intervention: Pindolol
Description: capsule of 20mg pindolol, single dose 1h before MDMA
Study: NCT00375258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: Loading dose of 1 gram then 1 gram by infusion over 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 0.9%
Description: Visual matched placebo
Study: NCT02897336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound-guided
Description: ultrasound-guided caudal epidural corticosteroid injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: interlaminar
Description: interlaminar epidural corticosteroid injection
Study: NCT04035226

Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be administered as a part of this study.
Study: NCT01731925

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lanreotide
Description: Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanreotide
Description: Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for sunitinib)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib 37.5 mg daily
Study: NCT04436744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Giredestrant
Description: During the window-of-opportunity phase (first 2 weeks) giredestrant will be taken orally once per day (QD) as a single agent. During the neoadjuvant treatment phase, giredestrant will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: During the window-of-opportunity phase (first 2 weeks), anastrozole 1 mg will be taken orally QD as a single agent. During the neoadjuvant treatment phase, anastrozole 1 mg will be taken orally QD on Days 1-28 of each 28-day cycle for a total of 4 cycles, in combination with palbociclib.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Palbociclib
Description: During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: During the neoadjuvant treatment phase, palbociclib 125 mg will be taken orally QD on Days 1-21 of a 28-day cycle for a total of 4 cycles.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery must be performed within a maximum of 14 days after the final cycle in the neoadjuvant treatment phase and ideally should occur as soon as possible after the last dose of study treatment.
Study: NCT01133847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Appropriate dosage to be individually determined; daily for 16 weeks
Study: NCT03817567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant anti-EGFR monoclonal antibody
Description: Experimental: Recombinant Anti-EGFR Monoclonal Antibody（SCT200）. Initially, SCT200 6.0mg/kg will be administered at day 1 every week for a maximum of 6 cycles. After 6 cycles SCT200 8.0mg/kg will be administered at day 2 every weeks until disease progression.
Study: NCT03354819

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified MBCT
Description: Compared with the original protocol of Mindfulness-based Cognitive Therapy (Segal et al., 2002), the modified MBCT protocol in this pilot study has the following changes:~Outline:~Session 1 Awareness and automatic pilot:~Session 2 Living in our head~Session 3 Gathering the scattered mind~Session 4 Recognizing aversion \& allowing~Session 5 Thoughts are not facts~Session 6 Take care of myself~Session 7 Maintaining and extending new learning

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SIRE on dementia
Description: The SIRE program includes routine education sessions on dementia care, caregiver skills training, and group sharing on caregiving tasks.~Outline:~1. Overview of dementia~2. Pharmacological and non-pharmacological treatment of dementia~3. BPSD in dementia care~4. Person center care~5. Advance planning in people with dementia~6. Principle of mindfulness~7. Non-pharmacological intervention on stress reduction
Study: NCT05136248

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intraarticular injection
Description: Ultrasound-guided intraarticular injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peng block
Description: Ultrasound-guided PENG block
Study: NCT03768869

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Risk: Inpatient Management
Description: Broad spectrum intravenous antibiotics. Daily blood work will be drawn, and patients will be monitored for fever and neutropenia in hospital.
Study: NCT04505982

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files

Intervention type: OTHER
Intervention: Data extraction from medical files
Description: Data extraction from medical files
Study: NCT03710941

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2477+REGN1033
Description: Single, sequential, repeat-dose Intravenous (IV) or matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Single, sequential, repeat-dose Intravenous (IV)
Study: NCT03016299

Intervention type: PROCEDURE
Intervention: microfracture techniques
Description: Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.

Intervention type: PROCEDURE
Intervention: microfracture techniques
Description: Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
Study: NCT02034604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naftofidil
Study: NCT02059980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response inhibition training
Description: This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Training
Description: This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
Study: NCT04014803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin
Description: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin
Description: Dual antiplatelet therapy with a P2Y12 inhibitor plus aspirin will be given according to the allocated arms in patients undergoing elective percutaneous coronary intervention for complex coronary lesion~1. Prasugrel plus Aspirin arm~2. Clopidogrel plus Aspirin arm
Study: NCT03410329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Physical activity
Study: NCT01821196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: biopsies will be evaluated with immunohistochemistry and gene expression studies